EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Influenza Vaccination and Cardiovascular Outcomes in Patients with Coronary Artery Diseases: A Placebo-Controlled Randomized Study, IVCAD

Mohammadmoein Dehesh iD, Sharareh Gholamin, Seyed-Mostafa Razavi, Ali Eskandari, Hossein Vakili, Mohammad Rahnavardi Azari, Yunzhi Wang, Ethan K Gough, Maryam Keshtkar-Jahromi iD

Vaccines · 27.04.2025 · 13 (5) · 472

DOI: 10.3390/vaccines13050472 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vaccines, online erschienen am 27.04.2025. Verfasst von Mohammadmoein Dehesh und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shahid Beheshti University of Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Influenza infection is associated with cardiovascular morbidity and mortality; however, the effect of influenza vaccination on cardiovascular outcomes is not fully understood. This clinical trial aimed to investigate the correlation between cardiovascular outcomes and influenza vaccine (FluVac) in coronary artery disease (CAD) subjects.

Methods

This was a randomized single-blinded placebo-controlled trial. Enrolled CAD subjects received 0.5 mL of 2007–2008 trivalent FluVac (15 µg hemagglutinin of each of Solomon Islands/3/2006 (H1N1), Wisconsin/67/2005 (H3N2), and Malaysia/2506/2004 (B)). The subjects were followed up at 1 month (hemagglutinin (HA) antibody titers) and at 12 months post-vaccination for evaluation of outcomes (influenza-like episodes, acute coronary syndrome (ACS), myocardial infarction (MI), coronary revascularization, and death).

Results

In total, 278 eligible CAD subjects were randomized to receive either FluVac (n = 137) or a placebo (n = 141), of which consequently 131 and 135 subjects completed the study. Cardiovascular deaths (3/131 [2.29%] vs. 3/135 [2.22%]) and all-cause deaths (4/131 [3.05%] vs. 4/135 [2.96%]) were similar in both groups. Adverse cardiovascular events, including ACS, MI, and coronary revascularization, were less frequent in the vaccine group but did not reach statistical significance. The magnitude of the antibody change and serologic response (≥4-fold HI titer rise) of all three antibodies were significantly higher in the vaccine group compared to the placebo but did not correlate with cardiovascular outcomes in the FluVac group.

Conclusions

The influenza vaccine may improve cardiovascular outcomes, though this improvement is not correlated with post-vaccination antibody titers. Despite the controversy, influenza vaccination is recommended in the CAD population (clinicaltrials.gov; NCT00607178).

Schlagwörter

Stichwörter der Autor:innen

antibodycardiovascular outcomecoronary artery disease (CAD)influenza vaccine

Autor:innen und Institutionen

  • Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA.
  • Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins University, Baltimore, MD 21187, USA.
  • Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA.
  • Department of Neurology, University of South Dakota Sanford School of Medicine, Sioux Falls, SD 57069, USA.
  • Department of Radiology, University of Iowa, Iowa City, IA 52242, USA.
  • Cardiovascular Research Center, Shahid Beheshti University of Medical Sciences, Tehran 1985717443, Iran.

ORCID-Profile: Mohammadmoein Dehesh, Maryam Keshtkar-Jahromi

Förderung

  • Shahid Beheshti University of Medical Sciences
  • Shahid Beheshti University of Medical Sciences, Tehran, Iran

Zitieren

APA

Dehesh, M., Gholamin, S., Razavi, S. M., Eskandari, A., Vakili, H., Rahnavardi Azari, M., Wang, Y., Gough, E. K., & Keshtkar-Jahromi, M. (2025). Influenza Vaccination and Cardiovascular Outcomes in Patients with Coronary Artery Diseases: A Placebo-Controlled Randomized Study, IVCAD. Vaccines, 13(5), 472. https://doi.org/10.3390/vaccines13050472

Vancouver

Dehesh M, Gholamin S, Razavi SM, Eskandari A, Vakili H, Rahnavardi Azari M, et al. Influenza Vaccination and Cardiovascular Outcomes in Patients with Coronary Artery Diseases: A Placebo-Controlled Randomized Study, IVCAD. Vaccines. 2025;13(5):472. doi:10.3390/vaccines13050472

BibTeX
@article{Dehesh2025,
  author = {Dehesh, Mohammadmoein and Gholamin, Sharareh and Razavi, Seyed-Mostafa and Eskandari, Ali and Vakili, Hossein and Rahnavardi Azari, Mohammad and Wang, Yunzhi and Gough, Ethan K and Keshtkar-Jahromi, Maryam},
  title = {Influenza Vaccination and Cardiovascular Outcomes in Patients with Coronary Artery Diseases: A Placebo-Controlled Randomized Study, IVCAD},
  journal = {Vaccines},
  year = {2025},
  volume = {13},
  number = {5},
  pages = {472},
  doi = {10.3390/vaccines13050472}
}
Kostenlos starten →